Stocks and Investing
Stocks and Investing
Fri, May 31, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, May 30, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Rajan Sharma Initiated (AZN) at Strong Buy and Held Target at $97 on, May 30th, 2024
Rajan Sharma of Goldman Sachs, Initiated "AstraZeneca PLC" (AZN) at Strong Buy and Held Target at $97 on, May 30th, 2024.
Rajan has made no other calls on AZN in the last 4 months.
There are 3 other peers that have a rating on AZN. Out of the 3 peers that are also analyzing AZN, 2 agree with Rajan's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Emmanuel Papada of "Deutsche Bank" Upgraded from Strong Sell to Hold on, Tuesday, April 16th, 2024
- Emmanuel Papadakis of "Deutsche Bank" Downgraded from Strong Buy to Hold on, Thursday, February 8th, 2024
This is the rating of the analyst that currently disagrees with Rajan
- Etzer Darout of "BMO Capital" Maintained at Buy with Increased Target to $82 on, Friday, April 26th, 2024
Contributing Sources